The General Hospital Corporation

Other

Massachusetts General Hospital Corporation

Aztherapies, Inc.

Seroton, Inc.

Harvard College

Northeastern University

Organix, Inc.

Biostream, Inc.

Fluoropharma, Inc.

Children's Medical Center Corporation

Molecular Insight Pharmaceuticals, Inc.

Intramedical Imaging, LLC

The General Hosptial Corporation

The Jmde Trust

David R Elmaleh

Alan J Fischman

Timothy M Shoup

John W Babich

Robert N Hanson

Choi Sung-Woon

Hongning Fu

Rudolph Emile Tanzi

Peter C Meltzer

Bertha K Madras

Rick A Rogers

Ana Griciuc

Choi Sungwoon

Hjalmar Brismar

Juan B Gonzalez

Maxim D Elmaleh

Alex Franzusoff

Paul C Zamecnik

Kevin P Maresca

Bruce R Zetter

Eliezer Rapaport

Farhad Daghighian

Simon C Robson

Kazue Takahashi

Jacqueline Banyard Bhisitkul

Sabrina Paganoni

Ghazaleh Sadri-Vakili

Eli Livni

Doron Weinfeld

Mikhail L Papisov

Boyan C Goumnerov

Choi Songwoon

Earl Weinstein

Ana Gricluc

The present disclosure relates to a method of treating one or more inflammation conditions induced by a coronavirus infection in a subject in need thereof, comprising administering a pharmaceutical composition comprising a compound of Formula I or Formula II:

Methods of treatment of coronavirus-induced inflammation conditions

Described herein are compounds and methods of treating or imaging a disease or disorder, such as Alzheimer's disease, Parkinson's disease, Huntington's disease, ischemic stroke, and prion disease, comprising administering a therapeutically effective amount of a cromolyn ester.

Cromolyn esters and uses thereof

Novel cromolyn analogs useful as imaging agents for detecting atherosclerotic plaques and for treating atherosclerosis and Alzheimer's Disease, and methods of making the cromolyn analogs, are disclosed. The cromolyn analogs have the general formula: wherein: X is OH, C-Calkoxyl; Y and Z are independently selected form a C-Calkyl, C-Calkoxyl, halogen, un-substituted or C-Csubstituted amine,F,F, or H; and n is 1, 2, or 3; and wherein for structure (I), if n are both 1 and Y and Z are both H and X is OH.

Cromolyn derivatives and related methods of imaging and treatment

Described herein are methods of treating neuron inflammation conditions, for example, Alzheimer's disease, Parkinson's disease, Huntington's disease, ischemic stroke, and prion disease, comprising administering a therapeutically effective amount of cromolyn or a cromolyn derivative compound.

Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases

A single or multi layered device (hereinafter alternately referred to as a 'capsule') of non-digestible material encapsulating an ingestible drug solution capable of slow solution release of stable solubilized drugs in water, saline, a buffer or lipophilic acceptable carriers. Methods for preparing the same and for safe, nearly constant dispensing of drugs following capsule swallowing. A safe, controlled flow release mechanism for the capsule's drug to the gastric system is disclosed.

Non-digestible, controlled release system for soluble drug delivery

Novel cromolyn analogs useful as imaging agents for detecting atherosclerotic plaques and for treating atherosclerosis and Alzheimer's Disease, and methods of making the cromolyn analogs, are disclosed. The cromolyn analogs have the general formula: wherein X is OH, C-Calkoxyl; Y and Z are independently selected from a C-Calkyl, C-Calkoxyl, halogen, un-substituted or C1-C6 substituted amine,F,F, or H; and n is 1, 2, or 3; and wherein for structure (I), if n are both 1 and Y and Z are both H and X is OH.

Described herein are self-assembling protein molecules for delivering a payload, for example, a toxic anti-cancer agent, a cancer immunotherapy, a toxic anti-cancer agent and a cancer immunotherapy, or an imaging agent, to specific tissues. Examples of self-assembled proteins include clathrin and derivatives of clathrin.

Self assembling molecules for targeted drug delivery

A dispenser for dispensing one or more dry-powder inhaler devices, having at least one compartment configured to hold at least one dry-powder inhaler device, the at least one dry-powder inhaler device comprising a casing enclosing at least one compartment containing an inhalable medicament covered by a cover, and at least one puncture mechanism comprising at least one pin structure operably aligned with the at least one compartment, and at least one obstruction internally located within the dispenser and adjacent to an opening, wherein, upon a dry-powder inhaler device being pulled from a dispenser, the at least one obstruction is configured to actuate the at least one puncture mechanism to extend the at least one pin structure into the casing, thereby puncturing the cover of the at least one compartment.

Dispenser for dry-powder inhalation devices

The present disclosure is directed to a composition comprising micronized cromolyn sodium, &#x3b1;-lactose, and a salt of fatty acid, wherein the &#x3b1;-lactose has a particle size distribution of Dof 45-70 &#x3bc;m, Dof 10-35 &#x3bc;m, and Dof 2-13 &#x3bc;m. The present disclosure is also directed to a method of treating Alzheimer's disease, amyloidosis-associated condition (AAC), traumatic brain injury, Huntington's disease, atherosclerosis, cytokine release syndrome (CRS), dementia, head injury, infection, neuroinflammation, prion disease, stroke, amyotrophic lateral sclerosis (ALS), Parkinson's disease, or asthma using the composition.

Powdered formulations of cromolyn sodium and alpha-lactose

The present invention relates to combination therapies for treating Alzheimer's disease or an amyloidosis-associated pathological condition comprising co-administering a therapeutically effective amount of a first compound, and a therapeutically effective amount of a second compound. In certain embodiments, the first compound or the second compound inhibits AB peptide polymerization; is an anti-inflammatory; improves cognitive function, mood, or social behavior; is associated with Tau or alpha-synuclein; or regulates amyloid peptide washout.

Combination therapies for the treatment of alzheimer's disease and related disorders

Methods of delivering cromolyn to a patient in need thereof, methods of treating amyloid-associated conditions and inflammatory or allergic lung diseases, and packs and kits comprising cromolyn are described.

Cromolyn compositions and methods thereof

One aspect of the present invention relates to compounds, compositions and methods for diagnosis and/or treatment of a subject suffering from an amyloidosis-associated pathological condition. In certain embodiments, the imaging and/or therapeutic agents of the instant invention may be administered to a subject for identification and/or treatment of amyloid deposits. A specific imaging method detects amyloid deposits by administering the imaging agent to the subject and detecting the spatial distribution of the agent. Differential accumulation of the agent is indicative of AD or an amyloidosis-associated pathological condition and can be monitored by using a PET or SPECT camera.

Compounds and compositions for the detection and treatment of Alzheimer's disease and related disorders

One aspect of the present invention relates to a method of preparing radiofluorinated substituted alkyl, cycloalkyl, aryl, and alkenyl compounds. In a preferred embodiment, potassium fluoride-18 is used. Another aspect of the invention relates to piperazine compounds containing fluorine-18 that are useful as imaging agents. In certain embodiments, the piperazine compounds contain a quaternary amine. Another aspect of the invention relates to arylphosphonium compounds containing fluorine-18 that are useful as imaging agents. In certain embodiments, the phosphonium compound is a tetraaryl phosphonium salt. Another aspect of the present invention relates to a method of obtaining a positron emission image of a mammal, comprising the steps of administering to a mammal a compound of the invention, and acquiring a positron emission spectrum of the mammal.

Catalytic radiofluorination

Novel cromolyn analogs useful as imaging agents for detecting atherosclerotic plaques and for treating atherosclerosis and Alzheimer's Disease, and methods of making the cromolyn analogs, are disclosed. The cromolyn analogs have the general formula: wherein: X is OH, C-Calkoxyl; Y and Z are independently selected form a C-Calkyl, C-Calkoxyl, halogen, un-substiuted or C-Csubstituted amine,F,F, or H; and n is 1, 2, or 3; and wherein for structure (I), if n are both 1 and Y and Z are both H and X is OH.

The invention is directed to a composition comprising cromolyn sodium and ibuprofen, wherein the cromolyn sodium is micronized and the cromolyn sodium and ibuprofen are present in a weight ratio of 1:1-2. In one embodiment, the ibuprofen is passed through a sieve, such as a 300 &#x3bc;m sieve and to methods of making the same.

Powdered formulations of cromolyn sodium and ibuprofen

Growing community of inventors

Newton, MA, United States of America

David R Elmaleh